Test Update: Pan-TRK IHC Testing for Vitrakvi

Effective 3/4/2019

In late 2018, the FDA approved Vitrakvi® (larotrectinib) for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.

PathGroup is pleased to announce the availability of Pan-TRK IHC (EPR17341) for this new indication. Orders within the SmartGenomics family of profiles will have TRK added based on the clinical context of the patient. The antibody is also available as a stand-alone immunohistochemistry test.


Click here for more information.